Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a high-grade brain tumour (classified as grade 3 or 4 by the World Health Organization), either confirmed by tissue testing or strongly suspected based on brain scans (though tissue confirmation will be required to remain in the trial)
- People whose tumour is located in the upper part of the brain (the cerebral hemispheres)
- People whose treatment plan includes radiation therapy aimed at treating the tumour
- People who are able to undergo MRI scans
- People of any gender, race, or ethnic background are welcome to be considered for this trial
Who may not be able to join:
- People who have a pacemaker, certain types of aneurysm clips (non-titanium), neurostimulators, cochlear implants, non-titanium metal near the eyes, or other implanted devices that could make having an MRI unsafe
- People who have significant health conditions that, in the opinion of the trial doctor, would make it unsafe or not possible to undergo MRI scans
- People whose tissue testing shows a low-grade brain tumour, or a non-cancerous or non-invasive brain tumour rather than a high-grade glioma
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bree R Eaton, MD, Emory University Hospital/Winship Cancer Institute
Phone: 404-778-3473
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Cho/NAA ratios at baseline in tumor and in regions of tumor recurrence in patients receiving standard of care radiotherapy; Incidence of adverse events; Feasibility of using sMRI to define proton therapy high dose (60Gy) target volumes for treatment delivery
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.